Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease

American Journal of Cardiology

Volumn 86, Issue 1, 2000, Pages 107-110

  Lepor, Norman E ^a   Gross, Stacey B ^a   Daley, William L ^b   Samuels, Bruce A ^a   Rizzo, Michael J ^b   Luko, Sean P ^a   Hickey, Ann ^a   Buchbinder, Neil A ^a   Naqvi, Tasneem Z ^c  

^a Heart Center of Los Angeles   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; FENFLURAMINE; PHENTERMINE;

ADULT; AORTA VALVE REGURGITATION; ARTICLE; DOPPLER ECHOCARDIOGRAPHY; HEART VALVE REGURGITATION; HUMAN; MAJOR CLINICAL STUDY; MITRAL VALVE REGURGITATION; PRIORITY JOURNAL; REGRESSION ANALYSIS; TRICUSPID VALVE REGURGITATION;

AORTIC VALVE INSUFFICIENCY; APPETITE DEPRESSANTS; BLOOD FLOW VELOCITY; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY, DOPPLER, COLOR; ELECTROCARDIOGRAPHY; FEMALE; FENFLURAMINE; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; MYOCARDIAL CONTRACTION; OBSERVATION; OBSERVER VARIATION; PHENTERMINE; RETROSPECTIVE STUDIES; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; VENTRICULAR FUNCTION, RIGHT;

EID: 0034237285     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)00840-7     Document Type: Article

References (19)

1. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine U.S. Department of Health and Human Services interim public health recommendations, November 1997 . Morb Mortal Wkly Rep. 46:1997;1061-1066.
2. Connolly H.M., Crary J.L., McGoon M.D., Hensrud D.D., Edwards B.S., Edwards W.D., Schaff H.V. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 337:1997;581-588.
3. Rassmussen S., Corya B.C., Glassman R.D. Valvular heart disease associated with fenfluramine-phentermine. (lett) N Engl J Med. 337:1997;1773.
4. Newman R. Mitral valve disease associated with use of anorexigenic medications. Ann Thoracic Surg. 64:1997;285.
5. Khan M.A., Herzog C.A., St. Peter J.V., Hartley G.G., Madlon-Kay R., Dick C.D., Asinger R.W., Vessey J.T. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med. 339:1998;713-718.
6. Jick H., Vasilakis C., Weinrauch L.A., Meier C.R., Jick S.S., Derby L.E. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 339:1998;719-724.
7. Burger A.J., Sherman H.B., Charlamb M.J., Kim J., Asinas L.A., Flickner S.R., Blackburn G.L. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol. 34:1999;1153-1158.
8. Dolan M.S., Castello R., St Aguirre F., Labovitz A.J. Quantitation of aortic regurgitation by Doppler echocardiography a practical approach . Am Heart J. 129:1995;1014-1020.
9. Perry G.J., Helmcke F., Nanda N.C., Byard C., Soto B. Evaluation of aortic insufficiency by Doppler color flow mapping. J Am Coll Cardiol. 9:1987;952-959.
10. Berger M., Haimowitz A., Van Tosh A., Berdoff R.L., Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol. 6:1985;359-365.
11. Yock P.G., Popp R.L. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation. 70:1984;657-662.
12. Currie P.J., Seward J.B., Chan K.L., Fyfe D.A., Hagler D.J., Mair D.D., Reeder G.S., Nishimura, Tajik A.J. Continuous wave Doppler determination of right ventricular pressure a simultaneous Doppler-catheterization study in 127 patients . J Am Coll Cardiol. 6:1985;750-756.
13. Spain M.G., Smith M.D., Grayburn P.A., Harlamert E.A., DeMaria A.N. Quantitative assessment of mitral regurgitation by Doppler color flow mapping angiographic and hemodynamic correlations . J Am Coll Cardiol. 13:1989;585-590.
14. Yamachika S., Reid C.L., Savani D., Meckel C., Paynter J., Knoll M., Jamison B., Gardin J.M. Usefulness of color Doppler proximal isovelocity surface area method in quantitating valvular regurgitation. J Am Soc Echocardiogr. 10:1997;159-168.
15. Hall S.A., Brickner M.E., Willett D.L., Irani W.N., Afridi I., Grayburn P.A. Assessment of mitral regurgitation severity by Doppler color flow mapping of the vena contracta. Circulation. 95:1997;636-642.
16. Weissman N.J., Tighe J.F., Gottdiener J.S., Gwynne J.T. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med. 339:1998;725-732.
17. Singh J.P., Evans J.C., Levy D., Larson M.G., Freed L.A., Fuller D.L., Lehman B., Benjamin E.J. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 83:1999;897-902.
18. Klein A.L., Burstow D.J., Tajik A.J., Zachariah P.K., Taliercio C.P., Taylor C.L., Bailey K.R., Seward J.B. Age related prevalence of valvular regurgitation in normal subjects a comprehensive color flow examination of 118 volunteers . J Am Soc Echocardiogr. 3:1990;54-63.
19. Bonow R.O., Carabello B., de Leon A.C. Jr, Edmunds L.H., Fedderly B.J., Freed M.D., Gaasch W.H., McKay C.R., Nishimura R.A., O'Gara P.T., O'Rourke R.A., Rahimtoola S.H. ACC/AHA guidelines for the management of patients with valvular heart disease a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on management of patients with valvular heart disease.) . J Am Coll Cardiol. 32:1998;1486-1588.